The STELLAR-303 trial is the first to show an immunotherapy-based regimen provides an overall survival benefit in microsatellite-stable CRC. Crucially, this benefit extends to patients with liver metastases, a subgroup that has historically shown profound resistance to immunotherapy, highlighting the drug's novel mechanism.
The success of both MOUNTAINEER (tucatinib/trastuzumab) and DESTINY-CRC02 (T-DXd) has introduced two effective, mechanistically different HER2-targeted therapies. This creates a new clinical challenge for oncologists: how to optimally sequence these agents, as there is no head-to-head data to guide the choice.
The KEYNOTE-177 trial allowed patients on the chemotherapy arm to cross over to pembrolizumab upon progression. Despite this, pembrolizumab showed a significant survival advantage, implying the actual benefit of using immunotherapy first-line is even greater than what the data shows.
The KRAS G12C inhibitor field is evolving at a breakneck pace. While sotorasib set an initial benchmark response rate of ~30% (in combo), newer agents like oloramoracep are already demonstrating response rates exceeding 45%, rapidly resetting efficacy expectations and treatment standards for this population.
While the encorafenib/cetuximab/chemotherapy triplet is the new first-line standard for BRAF V600E-mutant CRC, the trial's doublet arm (without chemo) also showed impressive outcomes. This establishes a highly effective, less toxic regimen for patients who are ineligible for or wish to avoid chemotherapy.
The COMET study found combining chemotherapy with atezolizumab did not improve overall survival versus atezolizumab alone. However, it nearly eliminated early progressive disease (2.8% vs. 32.4%), suggesting a critical role for patients with high tumor burden who cannot risk initial progression on monotherapy.